John Kovarik

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Concepts & Ideas

Procedures

Physiology

Phenomena

Metabolic Clearance Rate

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Kovarik John M; Huang Hsun-Lun A; Slade Alan; Sfikas Nikos; Chandler Patricia A
The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole.
Kovarik John M; Dole Kiran; Riviere Gilles-Jacques; Pommier Francoise; Maton Steve; Jin Yi; Lasseter Kenneth C; Schmouder Robert L
Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition.
Kovarik John M; Slade Alan; Riviere Gilles-Jacques; Neddermann Daniel; Maton Steve; Hunt Thomas L; Schmouder Robert L
The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of John Kovarik (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Kovarik John M; Huang Hsun-Lun A; Slade Alan; Sfikas Nikos; Chandler Patricia A
The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole.
British journal of clinical pharmacology 2009;68(3):381-5.
2009: Kovarik John M; Dole Kiran; Riviere Gilles-Jacques; Pommier Francoise; Maton Steve; Jin Yi; Lasseter Kenneth C; Schmouder Robert L
Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition.
Journal of clinical pharmacology 2009;49(2):212-8.
2008: Kovarik John M; Slade Alan; Riviere Gilles-Jacques; Neddermann Daniel; Maton Steve; Hunt Thomas L; Schmouder Robert L
The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects.
British journal of clinical pharmacology 2008;66(2):199-206.
2008: Kovarik John M; Lu Michael; Riviere Gilles-Jacques; Barbet Irene; Maton Steve; Goldwater D Ronald; Schmouder Robert L
The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects.
European journal of clinical pharmacology 2008;64(5):457-63.
2008: Kovarik John M; Riviere Gilles-Jacques; Neddermann Daniel; Maton Steve; Hunt Thomas L; Schmouder Robert L
A mechanistic study to assess whether isoproterenol can reverse the negative chronotropic effect of fingolimod.
Journal of clinical pharmacology 2008;48(3):303-10.
2008: Kovarik John M; Villamil Federico; Otero Alejandra; Levy Gary; Lynch Stephen; Cillo Umberto; Fischer Lutz; Nashan Björn; Pollard Steve; De Carlis Luciano
Cyclosporine pharmacokinetics and blood pressure responses after conversion to once-daily dosing in maintenance liver transplant patients.
Clinical transplantation 2008;22(1):68-75.
2007: Kovarik John M; Hartmann Stefan; Bartlett Michael; Riviere Gilles-Jacques; Neddermann Daniel; Wang Yibin; Port Andreas; Schmouder Robert L
Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects.
Biopharmaceutics & drug disposition 2007;28(2):97-104.
2007: Kovarik J M; Slade A; Voss B; Schmidli H; Riviere G J; Picard F; Sugita Y; Kawai R; Mee-Lee D; Schmouder R L
Ethnic sensitivity study of fingolimod in white and Asian subjects.
International journal of clinical pharmacology and therapeutics 2007;45(2):98-109.
2006: Kovarik J M; Tedesco-Silva H; Lorber M I; Foster C
Exposure-efficacy relationships of a fingolimod-everolimus regimen in kidney transplant patients at risk for delayed graft function.
Transplantation proceedings 2006;38(10):3479-82.
2006: Kovarik John M; Beyer Doris; Schmouder Robert L
Everolimus drug interactions: application of a classification system for clinical decision making.
Biopharmaceutics & drug disposition 2006;27(9):421-6.
2006: Schmouder Robert; Serra Denise; Wang Yibin; Kovarik John M; DiMarco John; Hunt Thomas L; Bastien Marie-Claude
FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects.
Journal of clinical pharmacology 2006;46(8):895-904.
2006: Kovarik John M; Noe Adele; Wang Yibin; Mueller Irene; DeNucci Gilberto; Schmouder Robert L
Differentiation of innovator versus generic cyclosporine via a drug interaction on sirolimus.
European journal of clinical pharmacology 2006;62(5):361-6.
2006: Kovarik John M; Snell Gregory I; Valentine Vincent; Aris Robert; Chan Charles K N; Schmidli Heinz; Pirron Ulrich
Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2006;25(4):440-6.
2006: Kovarik John M; Schmouder Robert L; Hartmann Stefan; Riviere Gilles-Jacques; Picard Franck; Voss Brigitta; Weiss Markus; Wagner Frank; Schmidt Hartmut H-J
Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function.
Journal of clinical pharmacology 2006;46(2):149-56.
2005: Kovarik J M; Beyer D; Bizot M N; Jiang Q; Allison M J; Schmouder R L
Pharmacokinetic interaction between verapamil and everolimus in healthy subjects.
British journal of clinical pharmacology 2005;60(4):434-7.
2005: Kovarik J M; Beyer D; Bizot M N; Jiang Q; Shenouda M; Schmouder R L
Blood concentrations of everolimus are markedly increased by ketoconazole.
Journal of clinical pharmacology 2005;45(5):514-8.
2005: Kovarik J M; Schmouder R L; Serra D; Wang Y; Wiegand H; Dilzer S C; Lasseter K C
FTY720 pharmacokinetics in mild to moderate hepatic impairment.
Journal of clinical pharmacology 2005;45(4):446-52.
2005: Kovarik J M; Beyer D; Bizot M N; Jiang Q; Shenouda M; Schmouder R L
Effect of multiple-dose erythromycin on everolimus pharmacokinetics.
European journal of clinical pharmacology 2005;61(1):35-8.
2004: Starling Randall C; Hare Joshua M; Hauptman Paul; McCurry Kenneth R; Mayer Hartmut W; Kovarik John M; Schmidli Heinz
Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2004;4(12):2126-31.
2004: Kovarik John M; Schmouder Robert L; Slade Alan J
Overview of FTY720 clinical pharmacokinetics and pharmacology.
Therapeutic drug monitoring 2004;26(6):585-7.
2004: Kovarik John M; Tedesco Helio; Pascual Julio; Civati Giovanni; Bizot Marie-Noelle; Geissler Johanna; Schmidli Heinz
Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation.
Therapeutic drug monitoring 2004;26(5):499-505.
2004: Kovarik John M; Schmouder Robert L; Barilla Denise; Büche Monika; Rouilly Marisel; Berthier Stephane; Wang Yibin; Van Saders Claudia; Mayer Thomas; Gottlieb Alice B
FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction.
The Annals of pharmacotherapy 2004;38(7-8):1153-8.
2004: Kovarik John M; Schmouder Robert; Barilla Denise; Riviere Gilles-Jacques; Wang Yibin; Hunt Thomas
Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects.
Journal of clinical pharmacology 2004;44(5):532-7.
2004: Kovarik John M; Schmouder Robert; Barilla Denise; Wang Yibin; Kraus Gerolf
Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects.
British journal of clinical pharmacology 2004;57(5):586-91.
2004: Kovarik John M
Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction.
Drugs of today (Barcelona, Spain : 1998) 2004;40(2):101-9.
2003: Kovarik John M; Dantal Jacques; Civati Giovanni; Rizzo Gaetano; Rouilly Marisel; Bettoni-Ristic Olga; Rordorf Christiane
Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2003;3(12):1576-80.
2003: Kovarik J M; Hoyer Peter F; Ettenger Robert; Punch Jeffrey; Soergel Marianne
Cyclosporine absorption profiles in pediatric kidney and liver transplant patients.
Pediatric nephrology (Berlin, Germany) 2003;18(12):1275-9.
2003: Kovarik John M; Eisen Howard; Dorent Richard; Mancini Donna; Vigano Mario; Rouilly Marisel; Hsu Chyi-Hung; Rordorf Christiane
Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2003;22(10):1117-25.
2003: Hoyer Peter F; Ettenger Robert; Kovarik John M; Webb Nicholas J A; Lemire Jacques; Mentser Mark; Mahan John; Loirat Chantal; Niaudet Patrick; VanDamme-Lombaerts R; Offner Gisela; Wehr Sabine; Moeller Virginia; Mayer Hartmut;
Everolimus in pediatric de nova renal transplant patients.
Transplantation 2003;75(12):2082-5.
2003: Kovarik John M; Kaplan Bruce; Silva Hélio Tedesco; Kahan Barry D; Dantal Jacques; McMahon Louis; Berthier Stephane; Hsu Chyi-Hung; Rordorf Christiane
Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2003;3(5):606-13.
2003: Kovarik John M; Noe Adele; Berthier Stephane; McMahon Louis; Langholff Wayne K; Marion Alan S; Hoyer Peter Friedrich; Ettenger Robert; Rordorf Christiane
Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics.
Journal of clinical pharmacology 2003;43(2):141-7.
2002: Kovarik John M; Offner Gisela; Broyer Michel; Niaudet Patrick; Loirat Chantal; Mentser Mark; Lemire Jacques; Crocker John F; Cochat Pierre; Clark Godfrey; Gerbeau Christophe; Chodoff Lawrence; Korn Alexander; Hall Michael
A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations.
Transplantation 2002;74(7):966-71.
2002: Kovarik John M; Barilla Denise; McMahon Louis; Wang Yibin; Kisicki James; Schmouder Robert
Administration diluents differentiate Neoral from a generic cyclosporine oral solution.
Clinical transplantation 2002;16(4):306-9.
2002: Kovarik John M; Gridelli Bruno G; Martin Steven; Rodeck Burkhard; Melter Michael; Dunn Stephen P; Merion Robert M; Tzakis Andreas G; Alonso Estella; Bucuvalas John; Sharp Harvey; Gerbeau Christophe; Chodoff Lawrence; Korn Alexander; Hall Michael
Basiliximab in pediatric liver transplantation: a pharmacokinetic-derived dosing algorithm.
Pediatric transplantation 2002;6(3):224-30.
2002: Kovarik John M; Hartmann Stefan; Figueiredo Joaquim; Rouilly Marisel; Port Andreas; Rordorf Christiane
Effect of rifampin on apparent clearance of everolimus.
The Annals of pharmacotherapy 2002;36(6):981-5.
2002: Van Damme-Lombaerts R; Webb N A Y; Hoyer P F; Mahan J; Lemire J; Ettenger R; McMahon L; Cambon N; Boger R; Kovarik J M;
Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients.
Pediatric transplantation 2002;6(2):147-52.
2002: Kovarik John M; Kaplan Bruce; Tedesco Silva Hélio; Kahan Barry D; Dantal Jacque; Vitko Stefan; Boger Robert; Rordorf Christiane
Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range.
Transplantation 2002;73(6):920-5.
2002: Kovarik John M; Hartmann Stefan; Figueiredo Joaquim; Rordorf Christiane; Golor Georg; Lison Arno; Budde Klemmens; Neumayer Hans H
Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants.
Pharmacotherapy 2002;22(2):154-9.
2002: Kovarik John M; Hartmann Stefan; Hubert Martine; Berthier Stephane; Schneider Werner; Rosenkranz Bernd; Rordorf Christiane
Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus.
Journal of clinical pharmacology 2002;42(2):222-8.
2002: Kovarik John M; Kalbag Jyoti; Figueiredo Joaquim; Rouilly Marisel; Frazier O'Bannon Larita; Rordorf Christiane
Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction.
Journal of clinical pharmacology 2002;42(1):95-9.
2001: Kovarik J M; Korn A; Chodoff L
Within-patient controlled assessment of the influence of basiliximab on cyclosporine in pediatric de novo renal transplant recipients.
Transplantation proceedings 2001;33(7-8):3172-3.
2001: Kovarik J M; Sabia H D; Figueiredo J; Zimmermann H; Reynolds C; Dilzer S C; Lasseter K; Rordorf C
Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment.
Clinical pharmacology and therapeutics 2001;70(5):425-30.
2001: Kovarik J M; Hsu C H; McMahon L; Berthier S; Rordorf C
Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications.
Clinical pharmacology and therapeutics 2001;70(3):247-54.
2001: Kovarik J M; Nashan B; Neuhaus P; Clavien P A; Gerbeau C; Hall M L; Korn A
A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation.
Clinical pharmacology and therapeutics 2001;69(4):201-9.
2001: Kovarik J M; Pescovitz M D; Sollinger H W; Kaplan B; Legendre C; Salmela K; Book B K; Gerbeau C; Girault D; Somberg K;
Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients.
Clinical transplantation 2001;15(2):123-30.
2001: Kovarik J M; Kahan B D; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
Clinical pharmacology and therapeutics 2001;69(1):48-56.
1999: Kovarik J M; Kahan B D; Rajagopalan P R; Bennett W; Mulloy L L; Gerbeau C; Hall M L
Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group.
Transplantation 1999;68(9):1288-94.
1999: Kovarik J M; Rigaudy L; Guerret M; Gerbeau C; Rost K L
Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin.
Clinical pharmacology and therapeutics 1999;66(4):391-400.
1999: Kovarik J M; Koelle E U
Cyclosporin pharmacokinetics in the elderly.
Drugs & aging 1999;15(3):197-205.
1999: Kovarik J M; Moore R; Wolf P; Abendroth D; Landsberg D; Soulillou J P; Gerbeau C; Schmidt A G
Screening for basiliximab exposure-response relationships in renal allotransplantation.
Clinical transplantation 1999;13(1 Pt 1):32-8.
1998: Kovarik J M; Purba H S; Pongowski M; Gerbeau C; Humbert H; Mueller E A
Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (mdr1) modulator: implications for coadministration.
Pharmacotherapy 1998;18(6):1230-6.
1998: Mueller E A; Kovarik J M; Pittrow D
Improving the oral absorption of cyclosporine in malabsorbers: a review of the Neoral Compassionate Need Program.
Transplantation proceedings 1998;30(5):1691-3.
1998: Primmett D R; Levine M; Kovarik J M; Mueller E A; Keown P A
Cyclosporine monitoring in patients with renal transplants: two- or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure.
Therapeutic drug monitoring 1998;20(3):276-83.
1997: Kovarik J M; Mueller E A; Richard F; Tetzloff W
Optimizing the absorption of valspodar, a P-glycoprotein modulator, Part II: Quantifying its pharmacokinetic variability and refining the bioavailability estimate.
Journal of clinical pharmacology 1997;37(11):1009-14.
1997: Mueller E A; Kovarik J M; Uresin Y; Preisig-Flückiger S S; Hensel S; Lücker P W; Holt B
Optimizing the absorption of valspodar, a P-glycoprotein modulator, Part I: Selecting an oral formulation and exploring its clinical pharmacokinetics/dynamics.
Journal of clinical pharmacology 1997;37(11):1001-8.
1997: Kovarik J M; Mueller E A; Gerbeau C; Tarral A; Francheteau P; Guerret M
Cyclosporine and nonsteroidal antiinflammatory drugs: exploring potential drug interactions and their implications for the treatment of rheumatoid arthritis.
Journal of clinical pharmacology 1997;37(4):336-43.
1996: Kovarik J M; Kurki P; Mueller E; Guerret M; Markert E; Alten R; Zeidler H; Genth-Stolzenburg S
Diclofenac combined with cyclosporine in treatment refractory rheumatoid arthritis: longitudinal safety assessment and evidence of a pharmacokinetic/dynamic interaction.
The Journal of rheumatology 1996;23(12):2033-8.
1996: Kovarik J M; Mueller E A; Richard F; Niese D; Halloran P F; Jeffery J; Paul L C; Keown P A
Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation.
Transplantation 1996;62(6):759-63.
1996: Kovarik J M; Mueller E A; Niese D
Clinical development of a cyclosporine microemulsion in transplantation.
Therapeutic drug monitoring 1996;18(4):429-34.
1996: Kovarik J M; Rawlings E; Sweny P; Fernando O; Moore R; Griffin P J; Fauchald P; Albrechtsen D; Sodal G; Nordal K; Amlot P L
Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation.
Transplantation proceedings 1996;28(2):913-4.
1996: Kovarik J M; Rawlings E; Sweny P; Fernando O; Moore R; Griffin P J; Fauchald P; Albrechtsen D; Sodal G; Nordal K; Amlot P L
Pharmacokinetics and immunodynamics of chimeric IL-2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients.
Transplant international : official journal of the European Society for Organ Transplantation 1996;9 Suppl 1():S32-3.
1995: Kovarik J M; Mueller E A; Kallay Z; Smith H T; Lison A E; Arns W; Renner E
Concentration-guided strategies in drug development: experience with a cyclosporine analog in transplantation.
Journal of clinical pharmacology 1995;35(12):1136-43.
1995: Kovarik J M; Mueller E A; Zehender H; Denouël J; Caplain H; Millerioux L
Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites.
Antimicrobial agents and chemotherapy 1995;39(12):2738-41.
1995: Mueller E A; Kallay Z; Kovarik J M; Richard F; Wiesinger O; Schmidt K; Scheele J
Bile-independent absorption of cyclosporine from a microemulsion formulation in liver transplant patients.
Transplantation 1995;60(5):515-7.
1995: Mueller E A; Kallay Z; Kovarik J M; Arns W; Renner E; Kutz K
Assessment of glomerular filtration rate after multiple administration of a new oral formulation of cyclosporine in clinically stable renal transplant patients.
Transplantation proceedings 1995;27(1):834-6.
1995: Holt D W; Mueller E A; Kovarik J M; van Bree J B; Richard F; Kutz K
Sandimmun neoral pharmacokinetics: impact of the new oral formulation.
Transplantation proceedings 1995;27(1):1434-7.
1995: Kovarik J M; Kallay Z; Mueller E A; van Bree J B; Arns W; Renner E
Acute effect of cyclosporin on renal function following the initial changeover to a microemulsion formulation in stable kidney transplant patients.
Transplant international : official journal of the European Society for Organ Transplantation 1995;8(5):335-9.
1994: Vernillet L; Kovarik J M; Freiburghaus R; Schaub P; Mueller E A; Niederberger W; Zehender H
Blood cyclosporin A and metabolite kinetic profiles after administration of Sandimmune soft gelatine capsules and Neoral in transplant recipients.
Transplantation proceedings 1994;26(5):2964-8.
1994: Mueller E A; Kovarik J M; Kutz K
Minor influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine.
Transplantation proceedings 1994;26(5):2957-8.
1994: Holt D W; Mueller E A; Kovarik J M; van Bree J B; Kutz K
The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine.
Transplantation proceedings 1994;26(5):2935-9.
1994: Kovarik J M; Vernillet L; Mueller E A; Freiburghaus R; Niederberger W; Kutz K
Cyclosporine disposition and metabolite profiles in renal transplant patients receiving a microemulsion formulation.
Therapeutic drug monitoring 1994;16(5):519-25.
1994: Kovarik J M; Mueller E A; van Bree J B; Flückiger S S; Lange H; Schmidt B; Boesken W H; Lison A E; Kutz K
Cyclosporine pharmacokinetics and variability from a microemulsion formulation--a multicenter investigation in kidney transplant patients.
Transplantation 1994;58(6):658-63.
1994: Kovarik J M; Mueller E A; van Bree J B; Arns W; Renner E; Kutz K
Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients.
Therapeutic drug monitoring 1994;16(3):232-7.
1994: Mueller E A; Kovarik J M; van Bree J B; Lison A E; Kutz K
Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients--a concentration-controlled comparison with the commercial formulation.
Transplantation 1994;57(8):1178-82.
1994: Mueller E A; Kovarik J M; van Bree J B; Tetzloff W; Grevel J; Kutz K
Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation.
Pharmaceutical research 1994;11(2):301-4.
1994: Mueller E A; Kovarik J M; van Bree J B; Grevel J; Lücker P W; Kutz K
Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation.
Pharmaceutical research 1994;11(1):151-5.
1994: Mueller E A; Kovarik J M; van Bree J B; Lison A E; Kutz K
Safety and steady-state pharmacokinetics of a new oral formulation of cyclosporin A in renal transplant patients.
Transplant international : official journal of the European Society for Organ Transplantation 1994;7 Suppl 1():S267-9.
1993: Kovarik J M; Mueller E A; Johnston A; Hitzenberger G; Kutz K
Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation.
Pharmacotherapy 1993;13(6):613-7.
1993: Mueller E A; Kovarik J M; Koelle E U; Merdjan H; Johnston A; Hitzenberger G
Pharmacokinetics of cyclosporine and multiple-dose diclofenac during coadministration.
Journal of clinical pharmacology 1993;33(10):936-43.
1993: Kovarik J M; Mueller E A; Gaber M; Johnston A; Jähnchen E
Pharmacokinetics of cyclosporine and steady-state aspirin during coadministration.
Journal of clinical pharmacology 1993;33(6):513-21.
1993: Sommers D K; Kovarik J M; Meyer E C; van Wyk M; Snyman J R; Blom M; Ott S; Grass P; Kutz K
Effects of diclofenac on isradipine pharmacokinetics and platelet aggregation in volunteers.
European journal of clinical pharmacology 1993;44(4):391-3.
1992: Kovarik J M; Kirkesseli S; Humbert H; Grass P; Kutz K
Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers.
The British journal of dermatology 1992;126 Suppl 39():8-13.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

John Kovarik

Research Profile (preview)

Chemicals & Drugs

Concepts & Ideas

Procedures

Physiology

Phenomena

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of John Kovarik (preview)

All Publications